VTVT

vTv Therapeutics Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-10

Figures on this page computed 2026-11-08 12:41 UTC

Last close

24.03USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-10

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.13 against 0.50 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.00x

1.69x

n/a

0.32x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

3 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-10

Sales0.00x
Its own average over 10 years, 3.0M.
Profit1.69x
Its own average over 10 years, -16.0M.
Free cash flown/a
Its own average over 9 years, -26.7M.
Debtn/a
Its own average over 5 years, 6.9M.
Price0.32x
Its own average over 11 years, 75. Market data, 2026-11-04

Sales is furthest from its own average, at 0.00 times.

Sales is 0.00 times its own 10-year average; Profit is 1.69 times its own 10-year average; Price is 0.32 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-10

Sales against its own 10-year average0.00
Source
filed
Statement
income
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
The filing itself
Profit against its own 10-year average1.69
Source
filed
Statement
income
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
The filing itself
Free cash flow against its own 9-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
The filing itself
Debt against its own 5-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001641489-26-000010
Reported in
USD
The filing itself
Price against its own 11-year average0.32Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD